Ciltacabtagene autoleucel,Pomalidomide,Bortezomib,Dexamethasone,Daratumumab
Janssen
['cilta-cel', 'cartitude-4', 'mmsm', 'cartitude']
 cartitude-4: cilta-cel vs soc (dpd, vpd) for 1-3 prior lines rrmm by median f/u 15.9 mos. primary endpt pfs
# 419 pts, 208 to cilta-cel, 211 to soc 32 (15%) did not receive cilta-cel after apheresis 60% high-risk cyto! 15% triple-class ref #mmsm #asco23 
Asst Professor at University of Chicago, specializing in (vanquishing) plasma cell disorders. I tweet about: Myeloma & MRD. https://t.co/mPeWg1QRrW